Evaluation of the clinical effect of osimertinib combined with dacomitinib (dacomitinib)

Osimertinib (Osimertinib) and dacomitinib (Dacomitinib) are Targeted drugs developed for patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Osimertinib is a third-generation EGFR inhibitor that has potent effects against T790M resistance mutations, while dacomitinib is a second-generation irreversible EGFR inhibitor. Although the mechanisms of the two are different, they can both effectively block the EGFR signaling pathway, thereby inhibiting the growth of tumor cells. Regarding the clinical application of osimertinib combined with dacomitinib, the safety and efficacy of its combination therapy are currently mainly explored.

Judging from existing clinical studies and case reports, the use of osimertinib or dacomitinib alone can significantly prolong the progression-free survival (PFS) of patients with EGFR mutationsNSCLC. However, there are relatively few studies on the combined use of two drugs, and some early clinical trials try to evaluate whether dual-target inhibition can overcome the problem of single-drug resistance and improve the therapeutic effect. Preliminary data suggest that combination therapy may exhibit synergistic antitumor activity in some drug-resistant patients, but with a corresponding increased risk of side effects.

In terms of safety, both osimertinib and dacomitinib can cause rash, diarrhea, stomatitis, etc.EGFR Common adverse reactions of inhibitors. These side effects may be cumulative or worsened when the drugs are used together, and patients need to receive close monitoring and supportive care. In addition, dacomitinib is usually more toxic than osimertinib, and the tolerability of the combination has become a focus of clinical attention, and the pros and cons need to be carefully weighed according to the patient's specific conditions.

Overall, the clinical research of osimertinib combined with dacomitinib is still in its early stages, and there are no large-scale randomized controlled trials to fully confirm its efficacy and safety. In the future, more clinical trials and real-world data will help clarify the optimal population, dosage regimen and management strategy for the combined use of these two drugs, providing better treatment options for patients with EGFR mutationNSCLC.

Reference materials:https://www.drugs.com